Related Experiment Video
Updated: Jun 11, 2025
07:08
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
734
The Evolutionary Forest of Pancreatic Cancer
Katelyn M Mullen1, Jungeui Hong1, Marc A Attiyeh1
1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Cancer Discovery
|October 8, 2024
Summary
Researchers analyzed the pancreatic cancer genome, focusing on evolutionary metrics to identify a new prognostic biomarker for pancreatic ductal adenocarcinoma (PDAC). This finding offers potential for improved diagnosis and treatment strategies.
Area of Science:
- Genomics
- Cancer Evolution
- Biomarker Discovery
Background:
- The genomic landscape of pancreatic ductal adenocarcinoma (PDAC) is known.
- However, its evolutionary trajectory concerning diagnostic stages and treatment challenges remains underexplored.
Purpose of the Study:
- To describe and quantify genomic features of PDAC using evolutionary metrics.
- To identify a novel prognostic biomarker for PDAC.
Main Methods:
- Genomic analysis of PDAC.
- Application of evolutionary metrics to genomic data.
Main Results:
- Quantification of genomic features in PDAC within an evolutionary context.
- Identification of a novel prognostic biomarker.
Conclusions:
- Genomic analysis using evolutionary metrics provides new insights into PDAC.
- A novel prognostic biomarker has been identified, potentially aiding in diagnosis and treatment.
Related Concept Videos
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
02:21Cancers Originate from Somatic Mutations in a Single Cell
11.8K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.8K
02:18Cancer
48.1K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
48.1K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:30Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K